Interpace Diagnostics Group Inc (NASDAQ:IDXG)’s share price was up 5.2% during trading on Friday . The stock traded as high as $0.82 and last traded at $0.81, approximately 206,900 shares traded hands during trading. A decline of 20% from the average daily volume of 259,584 shares. The stock had previously closed at $0.77.
Separately, HC Wainwright set a $2.00 target price on Interpace Diagnostics Group and gave the stock a “buy” rating in a report on Friday, July 19th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $3.33.
The company has a market cap of $29.03 million, a PE ratio of -1.88 and a beta of 2.31. The business has a 50-day simple moving average of $0.79 and a 200-day simple moving average of $0.78. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.06.
Interpace Diagnostics Group (NASDAQ:IDXG) last issued its quarterly earnings results on Tuesday, August 13th. The business services provider reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). The business had revenue of $6.27 million for the quarter, compared to analysts’ expectations of $6.70 million. Interpace Diagnostics Group had a negative return on equity of 42.91% and a negative net margin of 65.86%. On average, research analysts forecast that Interpace Diagnostics Group Inc will post -0.38 EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of the business. River & Mercantile Asset Management LLP purchased a new position in Interpace Diagnostics Group during the second quarter worth approximately $468,000. Cambridge Investment Research Advisors Inc. boosted its position in Interpace Diagnostics Group by 98.0% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 44,750 shares of the business services provider’s stock worth $32,000 after purchasing an additional 22,150 shares in the last quarter. Finally, Stonepine Capital Management LLC boosted its position in Interpace Diagnostics Group by 22.3% during the second quarter. Stonepine Capital Management LLC now owns 1,753,184 shares of the business services provider’s stock worth $1,271,000 after purchasing an additional 319,154 shares in the last quarter. Institutional investors own 20.68% of the company’s stock.
Interpace Diagnostics Group Company Profile (NASDAQ:IDXG)
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Read More: Do You Need a Fiduciary?
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.